Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting for PMX PMA

Company gains further clarity on the additional information required to advance its PMA review • FDA did not request an additional clinical ...

Spectral Medical Notes FDA Feedback on Toraymyxin Premarket Approval Application

Spectral Medical (EDT.TO) said Friday that while the US Food and Drug Administration had identified deficiencies in its premarket approval application for Toraymyxin, this will not "materially" change ...
Yahoo Finance

CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Spectral AI, Inc. (NASDAQ: MDAI), the reporting date of the financial results for the fourth ...
RTTNews

Spectral Gains Clarity Following FDA Meeting On PMA For Sepsis Therapy

As of June 30, 2026, Spectral held cash balance of CAD 803,000. EDT is currently trading at CAD 1.26 on the Toronto Stock Exchange. For comments and feedback contact: editorial@rttnews.com ...